postmenopausal women with hormone receptor–positive advanced breast cancer that had progressed or recurred during treatment with a nonsteroidal aromatase inhibitor randomized patients to exemestane with or without the mTOR inhibitor everolimus. 17 The results of
Search Results
Metastatic Breast Cancer, Version 1.2012
Featured Updates to the NCCN Guidelines
Robert W. Carlson, D. Craig Allred, Benjamin O. Anderson, Harold J. Burstein, Stephen B. Edge, William B. Farrar, Andres Forero, Sharon Hermes Giordano, Lori J. Goldstein, William J. Gradishar, Daniel F. Hayes, Clifford A. Hudis, Steven Jay Isakoff, Britt-Marie E. Ljung, David A. Mankoff, P. Kelly Marcom, Ingrid A. Mayer, Beryl McCormick, Lori J. Pierce, Elizabeth C. Reed, Mary Lou Smith, Hatem Soliman, George Somlo, Richard L. Theriault, John H. Ward, Antonio C. Wolff, Richard Zellars, Rashmi Kumar, and Dorothy A. Shead
Christopher P. Chung, Carolyn Behrendt, Louise Wong, Sarah Flores, and Joanne E. Mortimer
of 0 to 5, with 0 being “not bothersome” and 5 being “extremely bothersome.” 8 Adjuvant endocrine trials of aromatase inhibitors compared with tamoxifen have not reported an increase in bladder symptoms. 9 , 10 The Mind-Body Study reported more
Jonas A. de Souza, Mark J. Ratain, and A. Mark Fendrick
endocrine therapy with aromatase inhibitors (AIs) for women with hormone receptorpositive breast cancer is a prime example. Although some data support AI use for 5 years based on randomized clinical trials, evidence is still unclear beyond this duration, and
Robert W. Carlson, Susan Moench, Arti Hurria, Lodovico Balducci, Harold J. Burstein, Lori J. Goldstein, William J. Gradishar, Kevin S. Hughes, Mohammad Jahanzeb, Stuart M. Lichtman, Lawrence B. Marks, Joan S. McClure, Beryl McCormick, Lisle M. Nabell, Lori J. Pierce, Mary Lou Smith, Neal S. Topham, Tiffany A. Traina, John H. Ward, and Eric P. Winer
aromatase inhibitors. 27 , 28 Life Expectancy Estimation of survival was identified by many task force participants as a key factor in making treatment decisions for older women with breast cancer. Data from the U.S. Centers for Disease Control and
Cindy Railton, Sasha Lupichuk, Jennifer McCormick, Lihong Zhong, Jenny Jaeeun Ko, Barbara Walley, Anil A. Joy, and Janine Giese-Davis
to aromatase inhibitors (AIs). Analysis To summarize demographic, chart review, pharmacy, and interview data, we used descriptive statistics, SAS 9.3, and 2-tailed tests. Using chi-square and Fisher exact tests, we compared PCP versus cancer
Scott Ramsey and Veena Shankaran
: 36 – 46 . 23 Sedjo RL Devine S . Predictors of non-adherence to aromatase inhibitors among commercially insured women with breast cancer . Breast Cancer Res Treat 2011 ; 125 : 191 – 200 . 24 Kelley RK Venook AP
Therese B. Bevers
aromatase inhibitors (AIs) exemestane and anastrozole have shown even greater breast cancer risk reduction for women at increased risk of developing the disease. 5 , 6 However, the trials were small and these agents are not currently FDA-approved for this
Somasundaram Subramaniam, Jason A. Zell, and Pamela L. Kunz
improving progression-free survival in patients with hormone receptor-positive advanced breast cancer previously treated with nonsteroidal aromatase inhibitors. Common side effects of everolimus include stomatitis, rash, diarrhea, fatigue, and upper
Presenter: William J. Gradishar
cells become resistant to antiestrogen therapy. With knowledge of these pathways, these targets became druggable, he said. Figure 2. Examples of hormonal therapies for ER+ breast cancer: evidence of recent acceleration. Abbreviations: AI, aromatase
Julia C. Shih and Anthony J. Olszanski
. 6 Within cancer care, the earliest reports of nonadherence rates were documented in breast cancer with endocrine therapies, ranging from 12% to 59% with tamoxifen and 9% to 50% with aromatase inhibitors. 7 In a systematic review by Greer et al, 1